A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice.

about

A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice.

Item

http://www.wikidata.org/entity/Q50260488

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

A nano-liposome vaccine carryi ...... t antitumour activity in mice.

@en

A nano-liposome vaccine carryi ...... t antitumour activity in mice.

@nl

type

Item

label

A nano-liposome vaccine carryi ...... t antitumour activity in mice.

@en

A nano-liposome vaccine carryi ...... t antitumour activity in mice.

@nl

prefLabel

A nano-liposome vaccine carryi ...... t antitumour activity in mice.

@en

A nano-liposome vaccine carryi ...... t antitumour activity in mice.

@nl

P1476

A nano-liposome vaccine carryi ...... t antitumour activity in mice.

@en

P2093

Ali Badiee

http://www.w3.org/2001/XMLSchema#string

Atefeh Arab

http://www.w3.org/2001/XMLSchema#string

Atefeh Razazan

http://www.w3.org/2001/XMLSchema#string

Fatemeh Mosaffa

http://www.w3.org/2001/XMLSchema#string

Javad Behravan

http://www.w3.org/2001/XMLSchema#string

Mahmoud Reza Jaafari

http://www.w3.org/2001/XMLSchema#string

Nastaran Barati

http://www.w3.org/2001/XMLSchema#string

Zahra Gholizadeh

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

The immunobiology of cancer immunosurveillance and immunoediting

Antigen chemically coupled to the surface of liposomes are cross-presented to CD8+ T cells and induce potent antitumor immunity.

Liposome-coupled antigens are internalized by antigen-presenting cells via pinocytosis and cross-presented to CD8 T cells.

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.

Effector and memory CTL differentiation.

Liposomal delivery of CTL epitopes to dendritic cells.

The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.

P304

365-372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/1061186X.2017.1387788

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Amin Reza Nikpoor

P577

2017-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28972792

http://www.w3.org/2001/XMLSchema#string